ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences. Stifel 2024 Healthcare ConferenceFireside Chat on Monday, November 18th at 10:55 AM ET Stephens Annual Investment ConferenceFireside Chat on ...

MaxCyte, Inc. (MXCT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. I ...

Core Insights - MaxCyte, Inc. has appointed Cynthia Collins as a non-executive director to its Board of Directors, effective October 14, 2024, increasing the total board members to 10 [1][2]. Group 1: Appointment Details - Cynthia Collins brings over 40 years of experience in biotechnology and cell and gene medicines, including her role as CEO of Editas Medicine, where she was involved in the first in-vivo gene modified therapy [2]. - Collins has held various leadership positions, including CEO of Human Longevity Inc. and General Electric Healthcare's Cell Therapy and Lab Businesses [2]. Group 2: Current Board Memberships - Currently, Collins serves on the boards of several healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics, Certara, DermTech, Draper Laboratory, and Panavance Therapeutics [3]. Group 3: Educational Background - Cynthia Collins holds a Bachelor of Science degree in Microbiology from the University of Illinois, Urbana, and an MBA from The University of Chicago Booth School of Business [4]. Group 4: Company Overview - MaxCyte focuses on cell engineering to enhance the potential of cells for improving patient lives, with over 20 years of expertise in developing platforms for cell therapy [7]. - The ExPERT™ platform, based on Flow Electroporation® technology, supports the expanding cell therapy market from discovery to commercialization of next-generation cell-based medicines [7].

ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to d ...

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte's commercial ope ...

I've been following MaxCyte, Inc. ( MXCT ) for years now, since they IPO'ed on the London exchange (LSE: MXCT ). About a year ago, I wrote about MaxCyte's unique business model Jonquil Capital is a private investor, investment analyst, and writer from Smyrna, Georgia - the Jonquil city.Hopefully, by putting some words down in a page I can clarify my own thoughts on investment ideas and inspire worthwhile discussion and debate about the merits of these investments. I've been fully indoctrinated into the valu ...

Core Viewpoint - MaxCyte and Kamau Therapeutics have entered into a strategic platform license agreement, allowing Kamau to utilize MaxCyte's Flow Electroporation technology and ExPERT platform for research, clinical, and commercial purposes, while MaxCyte will receive licensing fees and program-related revenue [1][2]. Company Overview - MaxCyte is a cell-engineering company focused on advancing cell-based therapeutics and bioprocessing applications, with over 20 years of experience in developing enabling platform technologies [5]. - Kamau Therapeutics is a clinical-stage gene correction company that aims to develop therapies for serious genetic diseases, utilizing high-efficiency targeted gene integration based on homology-directed repair (HDR) technology [3][6]. Agreement Details - The agreement grants Kamau non-exclusive rights to MaxCyte's technologies, which will help optimize Kamau's clinical manufacturing process and expedite the development of its lead product candidate for sickle cell disease (SCD) [2][4]. - MaxCyte's ExPERT platform is designed for complex and scalable cell engineering, providing high transfection efficiency and enhanced functionality essential for next-generation biological therapeutics [4]. Product Development - Kamau's lead investigational program, nulacel, is in clinical development for sickle cell disease and aims to correct the mutation in the beta-globin gene, restoring normal hemoglobin levels in patients [3][7]. - The collaboration with MaxCyte is expected to enhance Kamau's capabilities in delivering curative therapies for genetic diseases with unmet medical needs [4][6].

ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the Virtual Craig-Hallum Capital Group Bioprocessing Conference on Thursday, September 19th at 9:30 am ET. A replay link of the event ...

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 35.71%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.09, delivering a surprise of 35.71%. Over the last four quarters, the company has surpassed ...

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, August 6, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cellengineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced its financial results for the second quarter ended June 30, 2024, and updates its 2024 guidan ...